MEDIPOST obtained a patent in Korea for commercializing a next-generation, high-efficiency technology for culturing stem cells.

This patented technology proves that pharmaceutical compositions based on high-efficiency stem cells are effective for regenerating lung tissues and blood vessels.

MEDIPOST has recently been working to develop a high-efficient stem cell culturing technology that can improve the quality and functions of stem cells while saving the production costs and extending the expiration date.

Naming this next-generation stem cell as ‘SMUP-Cell‘, MEDIPOST has been running a test production in a GMP facility and the treatment efficacy of this next-generation stem cell on specific diseases was theoretically verified for the first time acquiring this patent.